All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma Hub is happy to present a visual abstract representing key data from ELM-1 (NCT02290951), a phase I trial evaluating the safety and antitumor activity of odronextamab in patients with CD20+ B-cell malignancies. Preliminary results were previously reported in March 2021.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Preliminary results from phase I studies of CD20 × CD3 bispecific antibodies in R/R B-cell non-Hodgkin lymphoma
For patients with B-cell non-Hodgkin lymphoma (NHL) who relapse or become refractory to chemotherapy and anti-CD20 immunotherapy, there...
FDA places partial clinical hold on odronextamab trials in B-cell non-Hodgkin lymphomas
On December 14, 2020, it was reported that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on trials of odronextamab, a CD20 and...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox